IP Library Granted Patent US 12692268
Granted Patent B2
US 12692268 · App. 17/760,472 · Granted Jul 28, 2026

Imidazole derivative having protein kinase inhibitory activity, and use thereof

Inventors: Jung Mi Hah (Ansan-si, KR); Mi Young Jang (Ansan-si, KR)
Assignee: INDUSTRY-UNIVERSITY COOPERATION FOUNDATION HANYANG UNIVERSITY ERICA CAMPUS
C07D487/04A61P25/16A61P25/28
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12692268
App. No.
17/760,472
Granted
Jul 28, 2026
Kind
B2
Abstract

The present invention relates to: a novel imidazole derivative compound; an isomer thereof or a pharmaceutically acceptable salt thereof, and a pharmaceutical composition including the same. An imidazole derivative compound according to the present invention exhibits selective inhibitory activity against JNK, particularly JNK3, and thus can be used as a pharmaceutical composition for preventing and treating a degenerative brain disease (degenerative brain disease including Alzheimer's dementia, and Parkinson's disease).

Claims (92)

1 . A compound of the following Chemical Formula 1 or a pharmaceutically acceptable salt thereof:

in Chemical Formula 1,

R 1 is selected from the group consisting of

and a C 1 -C 6 alkyl,

R 2 is

herein,

n is an integer from 1 to 4,

m is an integer from 2 to 3,

carbon denoted as * is a chiral carbon,

Ar is selected from the group consisting of

 and naphthalenyl,

R 3 and R 4 are each independently a halogen atom, and

Z is a carbon or oxygen atom.

2 . The compound of claim 1 , wherein the compound of Chemical Formula 1 has a structure of the following Chemical Formula 2:

in Chemical Formula 2,

R 1 is selected from the group consisting of

and a C 1 -C 6 alkyl,

n is an integer from 1 to 4,

m is an integer from 2 to 3,

Ar is selected from the group consisting of

 and naphthalenyl,

R 3 and R 4 are each independently a halogen atom, and

Z is a carbon or oxygen atom.

3 . The compound of claim 1 , wherein the compound of Chemical Formula 1 has a structure of the following Chemical Formula 3:

in Chemical Formula 3,

R 1 is selected from the group consisting of

 and a C 1 -C 6 alkyl,

Ar is selected from the group consisting of

 and naphthalenyl,

R 3 and R 4 are each independently a halogen atom, and

Z is a carbon or oxygen atom.

4 . The compound of claim 1 , wherein the compound of Chemical Formula 1 has a structure of the following Chemical Formula 4:

in Chemical Formula 4,

R 1 is selected from the group consisting of

and a C 1 -C 6 alkyl,

n is an integer from 1 to 4,

m is an integer from 2 to 3,

Ar is selected from the group consisting of

 and naphthalenyl,

R 3 and R 4 are each independently a halogen atom, and

Z is a carbon or oxygen atom.

5 . The compound of claim 1 , wherein the compound of Chemical Formula 1 has a structure of the following Chemical Formula 5:

in Chemical Formula 5,

R 1 is selected from the group consisting of

and a C 1 -C 6 alkyl,

Ar is selected from the group consisting of

 and naphthalenyl,

R 3 and R 4 are each independently a halogen atom, and

Z is a carbon or oxygen atom.

6 . The compound of claim 1 , wherein the compound of Chemical Formula 1 has a structure of the following Chemical Formula 6:

in Chemical Formula 6,

R 1 is selected from the group consisting of

 and a C 1 -C 6 alkyl,

Ar is selected from the group consisting of

R 3 and R 4 are each independently a halogen atom, and

Z is a carbon or oxygen atom.

7 . The compound of claim 1 , wherein the compound of Chemical Formula 1 has a structure of the following Chemical Formula 7:

in Chemical Formula 7,

R 1 is selected from the group consisting of

 and a C 1 -C 6 alkyl,

Ar is

 and

R 3 and R 4 are each independently a halogen atom.

8 . The compound of claim 1 , wherein the compound of Chemical Formula 1 has a structure of the following Chemical Formula 8:

in Chemical Formula 8,

R 1 is selected from the group consisting of

 and a C 1 -C 6 alkyl,

Ar is selected from the group consisting of

 and naphthalenyl,

R 3 and R 4 are each independently a halogen atom, and

Z is a carbon or oxygen atom.

9 . The compound of claim 1 , wherein the compound of Chemical Formula 1 is

(S)-(1-(2-((1-(cyclopropanecarbonyl)piperidin-3-yl)amino)pyrimidin-4-yl)-2-(3,4-dichlorophenyl)-4,6-dihydropyrrolo[3,4-d]imidazol-5(1H)-yl)(4-hydroxypiperidin-1-yl)methanone;

(S)-(1-(2-((1-(cyclopropanecarbonyl)piperidin-3-yl)amino)pyrimidin-4-yl)-2-(3,4-dichlorophenyl)-4,6-dihydropyrrolo[3,4-d]imidazol-5(1H)-carboxamide;

(R)-1-(2-((1-(cyclopropanecarbonyl)pyrrolidin-3-yl)amino)pyrimidin-4-yl)-2-(3,4-dichlorophenyl)-4,6-dihydropyrrolo[3,4-d]imidazol-5(1H)-carboxamide;

(S)-1-(2-((1-(cyclopropanecarbonyl)pyrrolidin-3-yl)amino)pyrimidin-4-yl)-2-(3,4-dichlorophenyl)-4,6-dihydropyrrolo[3,4-d]imidazole-5(1H)-carboxamide;

(S)-1-(2-((1-(cyclobutanecarbonyl)piperidin-3-yl)amino)pyrimidin-4-yl)-2-(3,4-dichlorophenyl)-4,6-dihydropyrrolo[3,4-d]imidazole-5(1H)-carboxamide;

(S)-1-(2-((1-(cyclopentanecarbonyl)piperidin-3-yl)amino)pyrimidin-4-yl)-2-(3,4-dichlorophenyl)-4,6-dihydropyrrolo[3,4-d]imidazole-5(1H)-carboxamide;

(S)-1-(2-((1-(cyclopropanecarbonyl)piperidin-3-yl)amino)pyrimidin-4-yl)-2-(naphthalen-2-yl)-4,6-dihydropyrrolo[3,4-d]imidazole-5(1H)-carboxamide;

(R)-1-(2-((1-(cyclopropanecarbonyl)pyrrolidin-3-yl)amino)pyrimidin-4-yl)-2-(naphthalen-2-yl)-4,6-dihydropyrrolo[3,4-d]imidazole-5(1H)-carboxamide;

(S)-1-(2-((1-(cyclopropanecarbonyl)pyrrolidin-3-yl)amino)pyrimidin-4-yl)-2-(3,4-dichlorophenyl)-4,6-dihydropyrrolo[3,4-d]imidazole-5(1H)-carboxamide;

(S)-2-(benzo[d][1,3]dioxol-5-yl)-1-(2-((1-(cyclopropanecarbonyl)piperidin-3-yl)amino)pyrimidin-4-yl)-4,6-dihydropyrrolo[3,4-d]imidazole-5(1H)-carboxamide;

(R)-2-(benzo[d][1,3]dioxol-5-yl)-1-(2-((1-(cyclopropanecarbonyl)pyrrolidin-3-yl)amino)pyrimidin-4-yl)-4,6-dihydropyrrolo[3,4-d]imidazole-5(1H)-carboxamide;

(S)-2-(benzo[d][1,3]dioxol-5-yl)-1-(2-((1-(cyclopropanecarbonyl)pyrrolidin-3-yl)amino)pyrimidin-4-yl)-4,6-dihydropyrrolo[3,4-d]imidazole-5(1H)-carboxamide;

(S)-2-(benzo[d][1,3]dioxol-5-yl)-1-(2-((1-(cyclobutanecarbonyl)piperidin-3-yl)amino)pyrimidin-4-yl)-4,6-dihydropyrrolo[3,4-d]imidazole-5(1H)-carboxamide;

(S)-1-(2-((1-(cyclopropanecarbonyl)piperidin-3-yl)amino)pyrimidin-4-yl)-2-(2,3-dihydrobenzofuran-5-yl)-4,6-dihydropyrrolo[3,4-d]imidazole-5(1H)-carboxamide;

(R)-1-(2-((1-(cyclopropanecarbonyl)pyrrolidin-3-yl)amino)pyrimidin-4-yl)-2-(2,3-dihydrobenzofuran-5-yl)-4,6-dihydropyrrolo[3,4-d]imidazole-5(1H)-carboxamide; or

(S)-1-(2-((1-(cyclopropanecarbonyl)pyrrolidin-3-yl)amino)pyrimidin-4-yl)-2-(2,3-dihydrobenzofuran-5-yl)-4,6-dihydropyrrolo[3,4-d]imidazole-5(1H)-carboxamide.

10 . A pharmaceutical composition for preventing or treating a degenerative brain disease, comprising the compound or the pharmaceutically acceptable salt thereof according to claim 1 as an active ingredient.

11 . A method for treating a degenerative brain disease, comprising administering an effective amount of the compound or the pharmaceutically acceptable salt thereof according to claim 1 to a subject in need thereof.

12 . The method of claim 11 , wherein the degenerative brain disease is Alzheimer's dementia or Parkinson's disease.

13 . The method of claim 11 , wherein the compound inhibits the activity of c-Jun N-terminal kinase 3 (JNK3).